The approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy has been expanded by the FDA to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia, according to Novartis, the manufacturer of eltrombopag. Eltrombopag was also granted a breakthrough therapy designation as a counter measure for hematopoietic sub-syndrome of acute radiation syndrome.